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Abstract
Purpose: The study aims were to evaluate if the apparent diffusion coefficient (ADC) value could distinguish between 
breast lesions classified as B3 at core needle biopsy (CNB) that show or do not show atypia or malignancy at definitive 
histopathological examination (DHE) after surgical excision.  
Material and methods: From January 2013 to December 2017, 141 patients with a B3 breast lesion underwent magnetic 
resonance imaging and were included in the study. The ADC value was assessed drawing a ROI outlining the entire 
lesion, evaluating the mean (ADCmean) and minimum ADC values (ADCmin). 
Results: Both ADCmean and ADCmin values showed a statistically significant difference between B3 lesions without 
and with malignancy or, for B3a lesions, atypia at DHE. They both showed a statistically significant difference also 
between B3a lesions without or with atypia or malignancy at DHE, but only ADCmin (not ADCmean) showed statisti-
cally significant difference between B3b lesions without or with malignancy at DHE. 
Conclusions: The ADC value could help distinguish between B3a lesions without or with atypia/malignancy at DHE 
after surgical excision and between B3b lesions without or with malignancy at DHE. Therefore, it could be used to 
help guide the diagnostic-therapeutic pathway of these lesions, particularly of B3a lesions.
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Introduction 
Breast lesions classified as lesions of uncertain malignant 
potential (B3) are a heterogeneous group of abnormali-
ties with variable risk of associated malignancy. These le-
sions include atypical ductal hyperplasia (ADH), lobular 
intraepithelial neoplasia (LIN) 1-2, flat epithelial atypia 
(FEA), papillary lesions (PL), radial scars/complex scle-
rosing lesions (RS), and fibroepithelial lesions (FEL) [1]. 
These lesions can be subclassified according to the ab-
sence (B3a) or presence (B3b) of epithelial atypia [2-5]. 
Image-guided core needle biopsy (CNB) and vacuum- 
assisted biopsy (VAB) are essentials diagnostic proce-
dures, and B3 lesion diagnosis occurs in 4.5-12.8% of 
breast specimens [6-8]. However, borderline lesions 
mana gement is not simple because there is a signifi-
cant risk of malignancy underestimation [9,10]. Surgi-
cal excision has been for a long time considered the best 
treatment option for B3 lesions in order to achieve their 
definitive characterization. However, recently, the first 
and second international consensus conference on B3 le-
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sions recommended the expansion of the field of use of 
therapeutic VAB [11,12]. It is known that the apparent 
diffusion coefficient (ADC) value could help distinguish 
between benign, high-risk, and malignant breast lesions 
[13-17], but no previous studies have evaluated the per-
formance of the ADC value in distinguishing between 
B3b lesions without and with malignancy at definitive his-
topathological examination (DHE) after surgical excision, 
between B3a lesions without and with atypia/malignancy 
at DHE, and between B3a and B3b lesions. 
The study objectives were to evaluate if ADC value 
could differentiate between B3 and B3a lesions without 
and with atypia or malignancy at DHE after surgical ex-
cision and between B3b lesions without or with malig-
nancy at DHE. Another study aim was to assess breast 




From January 2013 to December 2017, 3986 CNBs were 
performed under sonographic guidance, and 384 (9.6%) 
B3 lesions were retrospectively collected. 
The inclusion criteria were as follows: borderline (B3) 
lesion diagnosis at CNB; breast magnetic resonance (MR) 
performed at our hospital between 1 and 2 months af-
ter CNB procedure; surgical excision biopsy and patho-
logical examination performed at our hospital within 
1 month after MRI and within 3 months after CNB. Exclu-
sion criteria were as follows: concomitant invasive breast 
cancer or ductal carcinoma in situ (DCIS) in the same 
breast in which borderline lesion was diagnosed; clinical 
evidence of haematoma at the CNB site at the time of MRI 
execution. 
According to these criteria, 141 patients (mean age 
47.9 ± 10.0 years; range 23-71) with 141 B3 lesions were 
selected by 4 radiologists (T.C., P.P, M.E., and S.B.F.) to be 
included in this study. Definitive post-surgical histopatho-
logical examination showed a maximum lesion diameter 
between 0.9 and 3.8 cm (mean 1.4 ± 0.4 cm). 
The study was approved by the institutional review 
board and ethics committee of our institution. Informed 
consent was obtained from all individual participants in-
cluded in the study. All procedures performed in studies 
involving human participants were in accordance with the 
ethical standards of the institutional and/or national re-
search committee and with the 1964 Helsinki declaration 
and its later amendments or comparable ethical standards.
Ultrasound-guided core needle biopsy
All the 141 sonography-guided CNBs were performed 
using a semi-automatic biopsy gun (Precisa, Hospital 
Service, Latina, Italy) with a 14-gauge needle, and 4 to 
8 (mean 5.5) cores were obtained during each CNB. In all 
cases local anaesthesia was performed (Lidocaine hydro-
chloride 20 mg/ml). All the lesion showed an important 
residual component visible at US examination after the 
procedure (always estimable as about more than 3/4 of 
the original lesion).
Breast magnetic resonance imaging protocol
Breast MRI was performed with a 1.5 T system (Achieva, 
Philips Medical Systems, Andover, MA) and a dedicated 
breast coil (SENSE Breast 7), using a standard protocol 
including the following sequences, each one with a field 
of view (FOV) of 340 × 340 mm:
–  axial short tau inversion recovery (STIR) sequence 
with a TR/TE of 7758/70; flip angle 90°; matrix size of 
272 × 222; slice thickness of 3 mm; slice spacing of 
3 mm; acquisition time of 4 minutes 39 seconds;
–  axial diffusion-weighted imaging (DWI) with a sin-
gle-shot echo-planar imaging (EPI); b value of 0 and 
800 s/mm2; TR/TE of 13,811/86; matrix size of 228 × 226; 
2 NEX; slice thickness of 3 mm; slice spacing of 3 mm 
and an acquisition time of 3 minutes 27 seconds;
–  axial T1-weighted 3D fat-suppressed (T1fs), spoiled gra-
dient-echo sequence (THRIVE) with TR/TE of 6.9/3.4; 
flip angle 12°; matrix size of 320 x 318; isotropic voxel of 
1 mm; acquisition time of 1 minute 17 seconds for each 
phase and a total acquisition time of 7 minutes and 53 
second; 1 phase before and 5 phases after gadobenate 
dimeglumine (Dotarem®; Guerbet BP 57400, F-95943 
RoissyCdGCedex, France) bolus injection (0.2 ml/kg, 
0.1 mmol/kg injected at 2.0 ml/s) followed by flushing 
with 20 ml of saline at 2.0 ml/s using an electronic pow-
er injector (Spectris MR Injector, Medrad).
Subtraction, multiplanar reconstruction (MPR) and 
maximum intensity projection (MIP) images, and ADC 
maps were also obtained. 
Report evaluation
Two radiologists with at least 10 years’ experience in breast 
MRI (G.G.M. and E.P.), who were blinded to the lesion 
definitive histopathological examination reports, assessed 
the MR images in consensus.
As regards quantitative ADC values, once the lesion 
was identified on DWI, a region of interest (ROI) was 
manually placed in each slice in which the lesion was 
detectable on the b = 800 s/mm2 DWI to encompass 
as much of the abnormality as possible, while staying 
within its border and taking care to avoid haemorrhagic 
and cystic areas [18]. Mean ADC value (ADCmean), which 
corresponds to the area-weighted average of the ADC 
values found within each lesion slice, and minimum 
ADC value (ADCmin), which corresponds to the lower 
ADC value found among the different slices, were used 
in the analysis.
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Statistical method
Definitive histopathological examinations were used as 
a gold standard in order to evaluate ADC value differenc-
es among B3 lesions. B3 lesions without epithelial atypia 
at CNB were considered B3a (PL, FEL, and RS without 
atypia), and the ones with epithelial atypia were considered 
B3b (ADH, LIN, FEA or PL, FEL, and RS with atypia at 
CNB). At DHE after surgical excision these lesions were 
further categorized in B3a without or with atypia or ma-
lignancy, and B3b without or with malignancy.
ADC values differences between groups were evaluat-
ed using t-test. The ADC threshold was chosen by the area 
under the ROC curve (AUC) and Youden index. AUCs 
were compared through the z-test. Qualitative variables 
were evaluated using the non-parametric Mann-Whitney 
U test. The statistical significance level was set at p < 0.05. 
All statistical analyses were performed using MedCalc 
Software v. 15.8 (Ostend, BEL).
Results
Histopathological findings
CNB diagnosis and specific CNB underestimation rates 
are reported in Table 1. The overall CNB underestima-
tion rate was 25.5%, and the malignancy underestima-
tion rate was 15.6%. DHE showed 16 DCISs, 4 IDCs, and 
2 ILCs. 10/34 ADHs were reported as malignant (7 DCISs, 
3 IDCs); 2/7 FEAs showed DCIS at DHE; 5/21 LINs were 
reported as malignant at DHE (2 DCISs, 2 ILCs, 1 IDCs); 
13/63 PLs were reported as atypical at DHE, and 4/63 
showed DCIS; 1/13 FELs showed DCIS, and 1/13 LINs. 
Magnetic resonance imaging findings
All the 141 B3 lesions were visible on DWI and ADC map. 
Therefore, all the 141 lesions were included in the ADC 
value analysis. ADCmean and ADCmin values of B3 lesions 
without (WO) and with (W) upgrade at DHE are reported 
in Table 2 (Figures 1-3). 
Statistical analysis
ADCmean and ADCmin values differences among B3 lesions 
are reported in Table 3. 
ADCmean and ADCmin AUC comparisons are shown in 
Figure 4. 
Discussion
DWI, quantified by ADC value, is an MRI technique that 
is used to evaluate the 3-dimensional mobility of water in 
vivo and enables indirect assessment of tissue microstruc-
ture. Advances in MR technology including echo-planar 
imaging, multichannel coils, and parallel imaging allowed 
the extension of the use of DWI in breast imaging, where 
it was first applied in 1997 by Englander et al. [18, 19]. 
In this study, ADC values were statistically different 
between B3 and B3a lesions without or with atypia or 
malignancy at DHE after surgical excision, between B3b 
lesions without or with malignancy at DHE, and between 
B3a and B3b lesions. The present study showed a better 
performance of the ADCmin value than ADCmean in pre-
dicting B3b lesions with malignancy at DHE or B3a le-
sions with atypia/malignancy at DHE.
The higher cellularity and the architectural changes of 
B3 lesions with associated atypia or malignancy could be 
the cause of the lower mean ADC values of these lesions, 
because in these conditions the motion of water molecules 
is more restricted [20-22].  
Diffusion restriction and low ADC values have been 
correlated with the presence of malignant lesions on non-






Underestimation rate at DHE: 
atypia* or malignancy**
ADH 34 10 (29.4%): 10** (29.4%) 
LIN 1-2 21 5 (23.8%): 5** (23.8%) 
FEA 7 2 (28.6%): 2** (28.6%) 
PL 63 17 (27.0%): 13* (20.6%), 4** (6.4%) 
RS 3 0 (0%)
FEL 13 2 (15.4%): 1* (7.7%), 1** (7.7%)
Total 141 36 (25.5%): 14* (9.9%), 22** (15.6%)
CNB – core needle biopsy, ADH – atypical ductal hyperplasia, LIN 1-2 – lobular intraephi-
telial neoplasia 1 or 2, FEA – flat epithelial atypia, PL – papillary lesion, RS – radial scar, 
FEL – fibroepithelial lesion
Table 2. B3 lesions ADCmean and ADCmin values
B3 lesions (n.) ADCmean ± SD  
× 10-3 mm2/s
ADCmin ± SD  
× 10-3 mm2/s
B3a+b (141) 1.417 ± 0.130 1.002 ± 0.170
B3a (79) 1.458 ± 0.145 1.081 ± 0.177
B3b (62) 1.365 ± 0.085 0.902 ± 0.090
B3a+bWO (105) 1.433 ± 0.133 1.052 ± 0.163
B3a+bW (36) 1.370 ± 0.111 0.860 ± 0.091
B3aWO (60) 1.490 ± 0.131 1.152 ± 0.126
B3aW (19) 1.354 ± 0.139 0.854 ± 0.113
B3bWO (45) 1.357 ± 0.089 0.915 ± 0.096
B3bW (17) 1.387 ± 0.069 0.866 ± 0.061
ADC – apparent diffusion coefficient, SD – standard deviation, B3a+bWO – B3 lesions with-
out upgrade at definitive histopathological examination (DHE), B3a+bW – B3 lesions with 
upgrade at DHE (upgrade to malignancy for B3b or, to malignancy or atypia for B3a lesions), 
B3aWO – B3a lesions without atypia or malignancy at DHE, B3aW – B3a lesions with atypia 
or malignancy at DHE, B3bWO – B3b lesions without malignancy at DHE, B3bW – B3b lesions 
with malignancy at DHE
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selected subjects [23-32], and previous studies showed that 
ADC values of normal breast tissue, benign lesions, and 
malignant lesions are related to the technical parameters of 
acquisition of MRI examination [33,34]. A previous study 
demonstrated that the mean ADC is significantly different 
between benign lesions and high-risk lesions [35].  
In this study the patients underwent an MRI exami-
nation with a maximum DWI b value of 800 s/mm2. This 
Table 3. ADCmean and ADCmin values differences among B3 lesions 
ADC B3 lesions p Threshold
× 10−3 mm2/s
Sensitivity Specificity AUC
ADCmean B3a vs. B3b < 0.0001 1.401 64.5 65.8 0.716
B3a+bWO vs. B3a+bW 0.0074 1.398 61.1 62.9 0.636
B3aWO vs. B3aW < 0.0001 1.418 68.4 73.3 0.757
B3bWO vs. B3bW 0.2814 1.381 58.8 48.9 0.590
ADCmin B3a vs. B3b < 0.0001 0.954 80.7 76.0 0.795
B3a+bWO vs. B3a+bW < 0.0001 0.903 77.8 77.1 0.849
B3aWO vs. B3aW < 0.0001 0.923 89.5 96.7 0.956
B3bWO vs. B3bW 0.0271 0.869 58.8 75.6 0.663
ADC – apparent diffusion coefficient, AUC – area under the ROC curve, B3a+bWO – B3 lesions without upgrade at definitive histopathological examination (DHE), B3a+bW – B3 lesions with 
upgrade at DHE (upgrade to malignancy for B3b or, to malignancy or atypia for B3a lesions), B3aWO – B3a lesions without atypia or malignancy at DHE, B3aW – B3a lesions with atypia or 
malignancy at DHE, B3bWO – B3b lesions without malignancy at DHE, B3bW – B3b lesions with malignancy at DHE
Figure 1. A 42-year-old woman with a 3.2-cm lesion in her right breast. The lesion appeared hyperintense on 
DWIs obtained at b = 0 (A) and b = 800 (B), and hypointense on ADC map (ADCmean 1.251 × 10
-3 mm2/s, ADCmin 
0.726 × 10-3 mm2/s). It was diagnosed as fibroepithelial lesion at core needle biopsy and upgraded to ductal 
carcinoma in situ at definitive histopathological examination after surgical excision 
Figure 2. A 43-year-old woman with a 1.0-cm lesion in her right breast. The lesion appeared slightly hyperin-
tense on DWIs obtained at b = 0 (A) and b = 800 (B), and hypointense on ADC map (ADCmean 1.413 × 10
-3 mm2/s, 
ADCmin 1.065 × 10
-3 mm2/s). It was diagnosed as lobular intra-ephitelial neoplasia (LIN) 1 at core needle biopsy 
and was confirmed to be LIN1 at definitive histopathological examination after surgical excision 
Figure 3. A 62-year-old woman with a 1.1-cm lesion in her right breast. The lesion appeared slightly hyperin-
tense on DWIs obtained at b = 0 (A) and b = 800 (B), and hypointense on ADC map (ADCmean 1.081 × 10
-3 mm2/s, 
ADCmin 0.722 × 10
-3 mm2/s). It was diagnosed as atypical ductal hyperplasia at vacuum-assisted biopsy and 
upgraded to IDC at definitive histopathological examination after surgical excision 
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value is commonly used in breast imaging [27] and was 
used in a previous study in this field [36]. 
To our knowledge, this is the first study that evaluated 
and found ADC value differences between B3b lesions with-
out and with malignancy at DHE after surgical excision, or 
between B3a lesions without and with atypia /malignancy at 
DHE, regardless of BI-RADS category. Moreover, this study 
found ADC value differences between B3a and B3b lesions.
Only 1 previous study assessed and found a significant 
correlation between B3 lesions upgraded to malignancy at 
surgery and ADC value, but the ADC value was evaluated 
in 23 breast lesions classified as MRI BI-RADS categories 
4 and 5 only [36].
A previous study reported a better performance of 
ADCmin value than ADCmean in distinguish between be-
nign and malignant lesions, and our study confirmed 
a statistically significant difference between ADCmin and 
ADCmean performance, although in another setting, be-
cause it was reached in 2 out of 4 cases [37]. 
Regarding the possible clinical implications of our 
findings, we think that the ADC value, especially the 
ADCmin value, could be used to help guide the diagnostic-
therapeutic pathway of these lesions. For example, B3 le-
sions with an ADC value under the thresholds reported 
in this study could be worthy of surgical excision or more 
frequent follow-up after VAB excision when the same MR 
scan and the same sequence settings are used. This could 
be particularly useful in patients who would otherwise not 
be referred for surgical excision or strict follow-up based 
on CNB results. In particular, our results show a possible 
clinical use of ADCmin in B3a lesions, in order to help dis-
criminate those lesions that show atypical or malignant 
foci at DHE. Confirmation of such findings from future 
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Figure 4. AUC ADCmean and ADCmin comparison between: A) B3 lesions upgraded and not upgraded (to malignancy for B3b, and to malignancy or atypia 
for B3a at definitive histopathological examination showed statistically significant difference (p < 0.0001, z statistic 4.289); B) B3a lesions upgraded and 
not upgraded to malignancy or atypia at definitive histopathological examination showed statistically significant difference (p = 0.0005, z statistic 3.508); 
C) B3b lesions upgraded and not upgraded to malignancy at definitive histopathological examination did not showed statistically significant difference 
(p = 0.5120, z statistic 0.653); D) B3a and B3b lesions did not showed statistically significant difference (p = 0.0692, z statistic 1.817)
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The present study has some limitations. First of all, 
it is a single-centre retrospective analysis, with a limited 
number of patients. Furthermore, ADC value inter-ob-
server variability, MRI BIRADS descriptors and assess-
ment categories were not assessed. Moreover, we are 
aware of the fact that performing MRI after CNB could 
be a shortcoming. However, this could be considered 
more useful in a clinical setting, because in daily practice 
MRI examinations are more frequently performed after 
this procedures. 
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